Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus

Lupus

Volumn 24, Issue 7, 2015, Pages 695-704

  Iwata, S ^a   Yamaoka, K ^a   Niiro, H ^b   Jabbarzadeh Tabrizi, S ^b   Wang, S P ^a   Kondo, M ^a   Yoshikawa, M ^a   Akashi, K ^b   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

B cell; neuropsychiatric lupus; renal lupus; Syk; Systemic lupus erythematosus; TRAF6

Indexed keywords

PREDNISOLONE; PROTEIN KINASE SYK; RITUXIMAB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; 2-(7-(3,4-DIMETHOXYPHENYL)IMIDAZO(1,2-C)PYRIMIDIN-5-YLAMINO)NICOTINAMIDE; CD19 ANTIGEN; CD27 ANTIGEN; NICOTINAMIDE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE; TAX1BP1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEMORY CELL; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; BIOSYNTHESIS; CASE CONTROL STUDY; DRUG EFFECTS; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD19; ANTIGENS, CD27; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NIACINAMIDE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; YOUNG ADULT;

EID: 84930828570     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314560424     Document Type: Article

References (32)

1. Martin F, Chan AC. B cell immunobiology in disease: Evolving concepts from the clinic. Annu Rev Immunol. 2006 ; 24: 467-496
2. Taniguchi T, Kobayashi T, Kondo J, et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem. 1991 ; 266: 15790-15796
3. Wong WS, Leong KP. Tyrosine kinase inhibitors: A new approach for asthma. Biochim Biophys Acta. 2004 ; 1697: 53-69
4. Beaven MA, Baumgartner RA. Downstream signals initiated in mast cells by Fc epsilon RI and other receptors. Curr Opin Immunol. 1996 ; 8: 766-772
5. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol. 2005 ; 115: 791-796
6. Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs. 2009 ; 12: 174-185
7. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009 ; 113: 3154-3160
8. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008 ; 58: 3309-3318
9. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010 ; 363: 1303-1312
10. Bahjat FR, Pine PR, Reitsma A, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008 ; 58: 1433-1444
11. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010 ; 62: 2086-2092
12. Kulathu Y, Grothe G, Reth M. Autoinhibition and adapter function of Syk. Immunol Rev. 2009 ; 232: 286-299
13. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naïve B cells. Eur J Immunol. 2006 ; 36: 810-816
14. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996 ; 97: 2063-2073
15. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med. 2006 ; 203: 553-561
16. Krieg AM. A role for Toll in autoimmunity. Nat Immunol. 2002 ; 3: 423-424
17. Rowland SL, Tremblay MM, Ellison JM, Stunz LL, Bishop GA, Hostager BS. A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling. J Immunol. 2007 ; 179: 4645-4653
18. Jalukar SV, Hostager BS, Bishop GA. Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions. J Immunol. 2000 ; 164: 623-630
19. Iwata S, Yamaoka K, Niiro H, et al. Amplification of toll-like receptor-mediated signaling through Syk in human B cell activation. J Allergy Clin Immunol. 2012 ; 129: 1594-1601
20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
21. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993 ; 86: 447-458
22. Bencivelli W, Vitali C, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992 ; 10: 549-554
23. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest. 1996 ; 98: 2549-2557
24. Nicholas MW, Dooley MA, Hogan SL, et al. A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol. 2008 ; 126: 189-201
25. Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 ; 162: 7088-7094
26. Bishop GA. The multifaceted roles of TRAFs in the regulation of B cell function. Nat Rev Immunol. 2004 ; 4: 775-786
27. Kobayashi T, Kim TS, Jacob A, et al. TRAF6 is required for generation of the B-1a B cell compartment as well as T cell-dependent and -independent humoral immune responses. PLoS One. 2009 ; 4: e4736 - e4736
28. Namjou B, Choi CB, Harley IT, et al. Evaluation of TRAF6 in a large multi-ancestral lupus cohort. Arthritis Rheum. 2012 ; 64: 1960-1969
29. Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 2008 ; 58: 1762-1773
30. Iwata S, Saito K, Tokunaga M, et al. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in long-term remission after B cell depletion therapy with rituximab. J Rheumatol. 2011 ; 38: 633-641
31. Iwata S, Saito K, Tokunaga M, Tanaka Y. B-cell or T-cell-dominant recurrence after rituximab therapy in patients with SLE. Ann Rheum Dis. 2012 ; 71: 1749-1750
32. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003 ; 101: 4500-4504